查詢結果分析
來源資料
相關文獻
- Usage of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) in Tumor EGFR Wild-type or Unknown Non-small Cell Lung Cancer
- 非小細胞肺癌標靶治療現況
- Patients Who Previously Responded to EGFR-TKI Treatment with Progression Responded to a Second EGFR-TKI Treatment after Challenge with Chemotherapy
- 非小細胞肺癌術前輔助性化學治療的經驗
- The Role of Radiotherapy for Advanced Non-Small Cell Lung Cancer
- Differential Display of mRNA in Human Lung Tissue and in Non-Small Cell Lung Cancer: A Preliminary Report
- 非小細胞肺癌的治療
- 晚期非小細胞肺癌之化學治療
- CA405之基因療法合併化學抗癌藥物對肺癌細胞之作用效果評估與機轉的探討(2)
- Treatment of Non-Small-Cell Lung Cancer: The Chinese Experience in a General Teaching Hospital
頁籤選單縮合
| 題 名 | Usage of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) in Tumor EGFR Wild-type or Unknown Non-small Cell Lung Cancer=使用上皮細胞生長因子接受體胳胺酸酶抑制劑於生長因子接受體為野生型或是不明的非小細胞肺癌 |
|---|---|
| 作 者 | 陳育民; 彭瑞鵬; 彭汪嘉康; | 書刊名 | 臺灣癌症醫學雜誌 |
| 卷 期 | 29:1 2013.03[民102.03] |
| 頁 次 | 頁3-13 |
| 分類號 | 416.224 |
| 關鍵詞 | 上皮細胞生長因子接受體; 得舒緩; 艾瑞莎; 非小細胞肺癌; 胳胺酸酶抑制劑; Epidermal growth factor receptor; Erlotinib; Gefitinib; Non-small cell lung cancer; Tyrosine kinase inhibitor; |
| 語 文 | 英文(English) |
| 中文摘要 | 近來十年針對已轉移的非小細胞肺癌的標靶治療的研究正是處於蓬勃發展的階段。在 I-PASS 研究發現「第四期非小細胞肺癌病患如腫瘤 EGFR 有活化性突變時,使用 EGFR-TKI 比使用化療可以延緩疾病惡化而且生活品質較好」以後,使用 EGFR-TKI 於 EGFR 有活化性突變的第四期非小細胞肺癌已成為第一線標準治療。化療則留給 EGFR 為 野生型或是不明的非小細胞肺癌的第一線治療。不管病患第一線接受標靶治療或是化 療,最終還是會復發而接受二線治療。有效的二線治療包括 docetaxel,pemetrexate,與 erlotinib。許多第三期的臨床試驗結果顯示使用 gefitinib 或是 erlotinib 於二線或三線的治 療效果並不比 docetaxel 或 pemetrexate 差。本篇回顧文章就是針對這些研究做分析,尤其 是評估這些藥品使用於 EGFR 野生型或不明的非小細胞肺癌病患的效益。 |
| 英文摘要 | Targeted therapy for metastatic non-small cell lung cancer (NSCLC) has been actively studied in the last decade. The use of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is considered the standard first-line treatment for metastatic NSCLC patients with tumor EGFR activating mutations, especially after the I-PASS and many similar studies showed longer progression-free survival and better quality of life when these patients received EGFR-TKIs, than when they received platinum-based chemotherapies. Chemotherapy was the remaining option for those patients whose tumor EGFR was wild-type or unknown. Almost all patients who received first-line treatment, either EGFR-TKI or chemotherapy, eventually relapsed and needed second-line salvage therapy. Documented effective second-line therapy for NSCLC patients who had been treated with platinum-based chemotherapy included docetaxel, pemetrexate, and erlotinib. Several phase III randomized trials showed that usage of gefitinib or erlotinib in a second-line or third-line setting was not inferior to docetaxel or pemetrexate treatment. The present review attempts to summarize previous studies of second-line treatment with EGFR-TKI or chemotherapy for NSCLC patients, paying special attention to compare the efficacies between different agents in those patients whose tumor EGFR was wild-type or unknown. |
本系統中英文摘要資訊取自各篇刊載內容。